If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

General resources

Home > Publications & resources > General resources

Below you can find useful resources relating to the NOVELTY study, and other useful links to sources of information about asthma and COPD.

Resource Name	Category	Description
Hyperpolarised ¹²⁹Xe gas MRI video	NOVELTY-related information	Hyperpolarised ¹²⁹Xe gas MRI is being used in the ADPro sub-study to image patient lungs. Watch the video to learn more about how hyperpolarised ¹²⁹Xe gas MRI works.	View
Respiratory Symptoms Questionnaire (RSQ) user guide	General asthma- or COPD-related information	A user guide for the Respiratory Symptoms Questionnaire (RSQ), including information on what it is, how it was developed and how it should be used.	Download
PRO video	NOVELTY-related information	This 3-minute video explains what PROs are and brings to life the importance of the patient's perspective in the management of asthma and COPD.	View
NOVELTY challenge	NOVELTY-related information	NOVELTY has many unique features that will help us to better understand obstructive airways diseases, to provide optimal, personalised healthcare to patients. This NOVELTY true/false challenge tests your knowledge in a fun and informative way. Do you accept the challenge?	View
Useful links	General asthma- or COPD-related information	Access resources that you may find useful to learn more about the NOVELTY study and general information about the treatment of asthma and COPD.	View

Resources containing data for patients in China that have not been published or presented are no longer included; these data were excluded from the analyses due to a change in regulations about data transfer in May 2019.

19 PARTICIPATING COUNTRIES^a

~12,000 ENROLLED PATIENTS^a

84% OF PATIENTS HAVE SPIROMETRY DATA^b

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study